NICHOLAS GENTILE

Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing, specifically on the Ensuring Innovation Act (S.415) and the Advancing Education on Biosimilars Act (s. 164). Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362)

Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing, specifically on the Ensuring Innovation Act (S.415) and the Advancing Education on Biosimilars Act (s. 164). Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362)

Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing, specifically on the Ensuring Innovation Act (S.415) and the Advancing Education on Biosimilars Act (s. 164). Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362)

Discussion with House and Senate offices on opioid addiction and the Mainstreaming Addiction Treatment Act of 2021 (H.R. 1384/S.445). Met with House and Senate to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Met with White House to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House offices, Senate offices, and agencies. Patient access to: pharmacist provided vaccinations COVID/flu/pediatric illnesses, COVID-19 testing, Emergency HIV prophylaxis, Initiation of oral antivirals for flu/COVID, Buprenorphine, Diabetes monitoring and management, Other pharmacist services authorized under state law.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its subagencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Contact FDA concerning the practice of White Bagging and Brown Bagging patient medications. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, MIPS/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, MIPS/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, MIPS/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, MIPS/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opioid addiction. Support with House offices on H.R. 5813 Overtime Reform and Enhancement Act. Discussion with House and Senate on 21st Century Cures Act H.R. 34.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opiod addiction. Discussion with Senate on antibiotic resistance.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opioid addiction. Discussion with Senate on antibiotic resistance. Support with House offices on H.R. 5813 Overtime Reform and Enhancement Act.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opioid addiction. Discussion with Senate on antibiotic resistance.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opioid addiction. Support with House offices on H.R. 5813 Overtime Reform and Enhancement Act. Discussion with House and Senate on 21st Century Cures Act H.R. 34.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opioid addiction. Discussion with Senate on antibiotic resistance. Support with House offices on H.R. 5813 Overtime Reform and Enhancement Act.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opioid addiction. Support with House offices on H.R. 5813 Overtime Reform and Enhancement Act. Discussion with House and Senate on 21st Century Cures Act H.R. 34.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with Senate on Chronic Condition legislation. Support for S. 524, Comprehensive Addiction and Recovery Act. Discussion with the House on increasing prescription drug pricing.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, MIPSA/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about recent FDA guidance on compounding and increasing prescription drug pricing.Communication with CMS regarding Part B payment demonstration.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, MIPSA/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about recent FDA guidance on compounding and increasing prescription drug pricing.Communication with CMS regarding Part B payment demonstration.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, MIPSA/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with Senate on Chronic Condition legislation. Discussion with House and Senate about recent FDA guidance on compounding and increasing prescription drug pricing.Communication with CMS regarding JW modifier, discussion with House and CMS regarding Part B payment demonstration.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opioid addiction. Discussion with Senate on antibiotic resistance. Support with House offices on H.R. 5813 Overtime Reform and Enhancement Act.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opioid addiction. Discussion with Senate on antibiotic resistance.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opioid addiction. Support with House offices on H.R. 5813 Overtime Reform and Enhancement Act. Discussion with House and Senate on 21st Century Cures Act H.R. 34.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opiod addiction. Discussion with Senate on antibiotic resistance.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act, and Section 11 of S. 2700, FDA and NIH Workforce Authorities Modernization Act. Contact concerning the Drug Quality and Security Act, all titles. Communication with the FDA on Generic Drug User Fee Act, Prescription Drug User Fee Act, Biosimilar User Fee Act, and electronic drug information.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act, and Section 11 of S. 2700, FDA and NIH Workforce Authorities Modernization Act. Contact concerning the Drug Quality and Security Act, all titles. Communication with the FDA on Generic Drug User Fee Act, Prescription Drug User Fee Act, Biosimilar User Fee Act, and electronic drug information. Expressed support for S. 524, Comprehensive Addiction and Recovery Act of 2016.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, MIPSA/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about recent FDA guidance on compounding and increasing prescription drug pricing.Communication with CMS regarding Part B payment demonstration.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with Senate on Chronic Condition legislation. Support for S. 524, Comprehensive Addiction and Recovery Act. Discussion with the House on increasing prescription drug pricing.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, MIPSA/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with Senate on Chronic Condition legislation. Discussion with House and Senate about recent FDA guidance on compounding and increasing prescription drug pricing.Communication with CMS regarding JW modifier, discussion with House and CMS regarding Part B payment demonstration.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, MIPSA/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about recent FDA guidance on compounding and increasing prescription drug pricing.Communication with CMS regarding Part B payment demonstration.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with Senate on Chronic Condition legislation. Support for S. 524, Comprehensive Addiction and Recovery Act. Discussion with the House on increasing prescription drug pricing.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Contact concerning the Drug Quality and Security Act, all titles. Communication with the FDA on Generic Drug User Fee Act, Prescription Drug User Fee Act, Biosimilar User Fee Act, and electronic drug information. Expressed support for S. 524, Comprehensive Addiction and Recovery Act of 2016.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act, and Section 11 of S. 2700, FDA and NIH Workforce Authorities Modernization Act. Contact concerning the Drug Quality and Security Act, all titles. Communication with the FDA on Generic Drug User Fee Act, Prescription Drug User Fee Act, Biosimilar User Fee Act, and electronic drug information. Expressed support for S. 524, Comprehensive Addiction and Recovery Act of 2016.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding.

Communication with Center for Medicare and medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Signed on to letter in support of H.R. 3539, Reinvigorating Antibiotic and Diagnostic Innovation Act of 2015. Support for H.R. 6, 21st Century Cures.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Support for H.R. 6, 21st Century Cures. Discussion with Senate on Chronic Condition legislation. Support for HR 3648, Gluten in Medicine Disclosure Act of 2015.

Communication with Center for Medicare and medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Support for H.R. 6, 21st Century Cures.

Communication with Center for Medicare and medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Signed on to letter in support of H.R. 3539, Reinvigorating Antibiotic and Diagnostic Innovation Act of 2015. Support for H.R. 6, 21st Century Cures.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Support for H.R. 6, 21st Century Cures. Discussion with Senate on Chronic Condition legislation. Support for HR 3648, Gluten in Medicine Disclosure Act of 2015.

Communication with Center for Medicare and medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program.

Communication with Center for Medicare and medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Support for H.R. 6, 21st Century Cures.

Communication with Center for Medicare and medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Signed on to letter in support of H.R. 3539, Reinvigorating Antibiotic and Diagnostic Innovation Act of 2015. Support for H.R. 6, 21st Century Cures.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Support for H.R. 6, 21st Century Cures. Discussion with Senate on Chronic Condition legislation. Support for HR 3648, Gluten in Medicine Disclosure Act of 2015.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding.

Communication with Center for Medicare and medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Support for H.R. 6, 21st Century Cures.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Support for H.R. 6, 21st Century Cures. Discussion with Senate on Chronic Condition legislation. Support for HR 3648, Gluten in Medicine Disclosure Act of 2015.

Communication with Center for Medicare and medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program.

Communication with Center for Medicare and medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Signed on to letter in support of H.R. 3539, Reinvigorating Antibiotic and Diagnostic Innovation Act of 2015. Support for H.R. 6, 21st Century Cures.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Contact concerning HRSA oversight of 340B drug discount program. Communication with the OIG on Compendia . Contact concerning the Drug Quality and Security Act, H.R. 3204, all titles. Communication with the FDA on labeling of generic medications and drugs containing salts. Communication with FTC on biosimilars. Support for H.R. 3742, all titles, theAntibiotic Development to Advance Patient Treatment Act.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Contact concerning HRSA oversight of 340B drug discount program. Contact concerning the Drug Quality and Security Act, H.R. 3204, all titles. Communication with the FDA on the labeling of generic medications and biosimilars. Communication with FTC on biosimilars.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Contact concerning HRSA oversight of 340B drug discount program. Communication with the GAO on compounding. Contact concerning the Drug Quality and Security Act, H.R. 3204, all titles. Communication with the FDA on labeling of generic medications and drugs containing salts. Communication with FTCon biosimilars. Support for H.R. 3742, all titles, theAntibiotic Development to Advance patient Treatment Act.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Contact concerning HRSA oversight of 340B drug discount program. Communication with the GAO on compounding. Contact concerning the Drug Quality and Security Act, H.R. 3204, all titles. Communication with the FDA on labeling of generic medications and drugs containing salts. Communication with FTCon biosimilars. Support for H.R. 3742, all titles, theAntibiotic Development to Advance patient Treatment Act.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Contact concerning HRSA oversight of 340B drug discount program. Communication with the OIG on Compendia . Contact concerning the Drug Quality and Security Act, H.R. 3204, all titles. Communication with the FDA on labeling of generic medications and drugs containing salts. Communication with FTC on biosimilars. Support for H.R. 3742, all titles, theAntibiotic Development to Advance Patient Treatment Act.

Communication with Centers for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 4190, a bill that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program.

Communication with Centers for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, and annual payment updates. Support for HR 4190, a bill that would amend Title 18 of the Social Security Act to provide for coverage under the Medicare Program of pharmacist services.

Communication with Centers for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, and annual payment updates. Support for HR 4190, a bill that would amend Title 18 of the Social Security Act to provide for coverage under the Medicare Program of pharmacist services.

Communication with Centers for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, and annual payment updates. Support for HR 4190, a bill that would amend Title 18 of the Social Security Act to provide for coverage under the Medicare Program of pharmacist services.

Contact concerning FDA authority to manage drug shortages and regulation of pharmacy compounding. Contact concerning HRSA oversight of 340B drug discount program. Communication with the FDA on the REMS program. Contact concerning S. 959, Pharmaceutical Compounding and Quality Accountability Act, (all sections) to address FDA oversight of certain drug compounding entities. Contact concerning HR 3204 (all sections) the Drug Quality and Security Act.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Contact concerning HRSA oversight of 340B drug discount program. Communication with the FDA on the REMS program. Contact concerning the Drug Quality and Security Act, H.R. 3204, all titles.

Communication with Centers for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, and annual payment updates. Communication with the Office of the Inspector General regarding Conflicts of Interest for Compendia recognized by Medicare. Support for Grassley/Carper Amendment #7 to the SGR Repeal and Medicare Beneficiary Access Act of 2013 (S. 1871), which would list pharmacists as providers within Accountable Care Organizations.

Contact concerning FDA authority to manage drug shortages and regulation of pharmacy compounding. Contact concerning HRSA oversight of 340B drug discount program. Communication with the FDA on the REMS program. Contact concerning S. 959, Pharmaceutical Compounding and Quality Accountability Act, (all sections) to address FDA oversight of certain drug compounding entities. Contact concerning HR 3204 (all sections) the Drug Quality and Security Act.